Roncolato FT, O'Connell RL, Joly F, et al. - In this GCIG symptom benefit study of 378 women, experts evaluated health-related quality of life (HRQL) with EORTC QLQ-C30/QLQ-OV28 in order to enhance patient preference for chemotherapy on the basis of a nomogram prognosticating PFS. Baseline HRQL was discovered to be simple to measure, predictive of PFS and OS and it could help with clinical decision making and treatment guidance for women with PPSROC ≥ 3 when used in conjunction with clinicopathological prognostic factors.